Drug Shortage Report for EXELON
| Report ID | 178295 |
| Drug Identification Number | 02245240 |
| Brand name | EXELON |
| Common or Proper name | Rivastigmine Oral Solution |
| Company Name | KNIGHT THERAPEUTICS INC. |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | ORAL ORAL |
| Packaging size | 120 mL bottle |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-12-31 |
| Actual start date | 2023-01-31 |
| Estimated end date | 2023-10-31 |
| Actual end date | 2023-10-31 |
| Shortage status | Resolved |
| Updated date | 2023-11-06 |
| Company comments | Company contact: supply@knighttx.com |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 3400 DE MAISONNEUVE BLVD W MONTREAL, QUEBEC CANADA H3Z 3B8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v10 | 2023-11-06 | English | Compare |
| v9 | 2023-10-02 | French | Compare |
| v8 | 2023-10-02 | English | Compare |
| v7 | 2023-06-15 | French | Compare |
| v6 | 2023-06-15 | English | Compare |
| v5 | 2023-02-15 | French | Compare |
| v4 | 2023-02-15 | English | Compare |
| v3 | 2023-01-01 | English | Compare |
| v2 | 2022-12-13 | French | Compare |
| v1 | 2022-12-13 | English | Compare |
Showing 1 to 10 of 10